1. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors
   Ralf-Dieter Hofheinz et al, 2017, Critical Reviews in Oncology/Hematology CrossRef
2. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
   Kenar D. Jhaveri et al, 2017, Kidney International Reports CrossRef
3. Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies
   David Reeves, 2017, A Worldwide Yearly Survey of New Data in Adverse Drug Reactions CrossRef
4. Targeted cancer therapies (biologics)
   VIDHI DESAI et al, 2020, Onco-Nephrology CrossRef
5. Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
   Bo Zhang et al, 2018, Oncology Letters CrossRef
6. The possibility of development of hypomagnesemia of surgical patients
   S. V Sviridov et al, 2017, Medical Journal of the Russian Federation CrossRef
7. Risk Evaluation of Proton Pump Inhibitors for Panitumumab-Related Hypomagnesemia in Patients with Metastatic Colorectal Cancer
   Hideyuki Katsura et al, 2024, Biological and Pharmaceutical Bulletin CrossRef
8. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study
   Christoph Schulz et al, 2020, Anti-Cancer Drugs CrossRef
9. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
   Satoru Muto et al, 2023, International Journal of Clinical Oncology CrossRef